Market Overview

UPDATE: ISI Group Cuts PT to $39 on Charles River Laboratories Following Negative Guidance

Share:
Related CRL
Benzinga's Top Upgrades, Downgrades For December 13, 2017
Lightning Round: Jim Cramer Advises His Viewers On Mallinckrodt, GoPro And More
Charles River Labs International Sees IBD RS Rating Rise To 72 (Investor's Business Daily)

ISI Group reiterated its Underweight rating on Charles River Laboratories (NYSE: CRL) and lowered its price target from $40.50 to $39.

ISI Group commented, "As a result of today's 2013 guidance announcement, we are lowering CRL's FY13 EPS from $3.10 to $3.00 and FY14 EPS from $3.45 to $3.25. These EPS changes stem from lower operating margin expectations due to the aforementioned investment headwinds. Despite the improved revenue outlook, limited visibility across the business (ex strategic deals) and a challenged OM outlook will limit P/E expansion, and in turn, cap shares in the upper $30s."

Charles River Laboratories closed at $36.55 on Tuesday.

Latest Ratings for CRL

DateFirmActionFromTo
Dec 2017ArgusInitiates Coverage OnBuy
Nov 2017JefferiesMaintainsBuy
Nov 2017Bank of AmericaMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CRL)

View Comments and Join the Discussion!

Partner Center